1. Home
  2. STGW vs AVXL Comparison

STGW vs AVXL Comparison

Compare STGW & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STGW
  • AVXL
  • Stock Information
  • Founded
  • STGW 1980
  • AVXL 2004
  • Country
  • STGW United States
  • AVXL United States
  • Employees
  • STGW N/A
  • AVXL N/A
  • Industry
  • STGW
  • AVXL Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • STGW
  • AVXL Health Care
  • Exchange
  • STGW Nasdaq
  • AVXL Nasdaq
  • Market Cap
  • STGW 662.6M
  • AVXL 779.5M
  • IPO Year
  • STGW N/A
  • AVXL N/A
  • Fundamental
  • Price
  • STGW $6.63
  • AVXL $9.85
  • Analyst Decision
  • STGW Strong Buy
  • AVXL Strong Buy
  • Analyst Count
  • STGW 5
  • AVXL 2
  • Target Price
  • STGW $8.50
  • AVXL $44.00
  • AVG Volume (30 Days)
  • STGW 345.5K
  • AVXL 2.8M
  • Earning Date
  • STGW 02-25-2025
  • AVXL 02-05-2025
  • Dividend Yield
  • STGW N/A
  • AVXL N/A
  • EPS Growth
  • STGW N/A
  • AVXL N/A
  • EPS
  • STGW 0.00
  • AVXL N/A
  • Revenue
  • STGW $2,707,403,000.00
  • AVXL N/A
  • Revenue This Year
  • STGW $13.05
  • AVXL N/A
  • Revenue Next Year
  • STGW N/A
  • AVXL N/A
  • P/E Ratio
  • STGW $2,390.91
  • AVXL N/A
  • Revenue Growth
  • STGW 4.92
  • AVXL N/A
  • 52 Week Low
  • STGW $4.88
  • AVXL $3.25
  • 52 Week High
  • STGW $8.18
  • AVXL $14.44
  • Technical
  • Relative Strength Index (RSI)
  • STGW 49.63
  • AVXL 47.08
  • Support Level
  • STGW $5.81
  • AVXL $8.97
  • Resistance Level
  • STGW $6.57
  • AVXL $11.68
  • Average True Range (ATR)
  • STGW 0.23
  • AVXL 1.16
  • MACD
  • STGW 0.05
  • AVXL -0.36
  • Stochastic Oscillator
  • STGW 92.13
  • AVXL 16.67

About STGW Stagwell Inc.

Stagwell Inc is the challenger holding company built to transform marketing. It delivers scaled creative performance for the world's ambitious brands, connecting culture-moving creativity with a technology to harmonize the art and science of marketing. The company's segments include Integrated Agencies Network; Brand Performance Network; Communications Network and other. It generates maximum revenue from the Integrated Agencies Network segment. Geographically, it derives a majority of its revenue from the United States.

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.

Share on Social Networks: